VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 356 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2016. The put-call ratio across all filers is 1.00 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $59,515,000 | -40.9% | 4,098,817 | 0.0% | 13.87% | -38.6% |
| Q3 2016 | $100,626,000 | +17.8% | 4,098,817 | -3.4% | 22.60% | +52.8% |
| Q2 2016 | $85,434,000 | -12.7% | 4,242,012 | +14.0% | 14.79% | -6.5% |
| Q1 2016 | $97,901,000 | -48.7% | 3,722,464 | +98.5% | 15.82% | -27.1% |
| Q4 2015 | $190,655,000 | – | 1,875,600 | – | 21.68% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
| Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
| LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
| Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
| FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
| Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
| Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
| Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
| Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
| ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |